Latest / Pharmacy Podcast Network / Pain Pearls: Part 1 | Pain Pod
Transcript
- 0:07Speaker 1: You are listening to the Pharmacy Podcast Network.
- 0:17Speaker 2: This is the Pain Pod. You want to shit pain
- 0:22Speaker 2: look at me?
- 0:29Speaker 1: Welcome to the Pain Pod, the podcast for all things
- 0:34Speaker 1: pain management, hosted by the Pain Guy.
- 0:38Speaker 2: Doctor Mark Grove.
- 0:43Speaker 1: We'll be collaborating with numerous pain management experts talking about
- 0:48Speaker 1: substance usage disorders, the latest treatment modalities, and most important
- 0:53Speaker 1: important focusing on the pain of our patients as leading
- 0:57Speaker 1: providers of pain care. And now here's our host, a
- 1:03Speaker 1: man wanted in all fifty states, a suburban city like
- 1:08Speaker 1: mountain man without the beard, from the hills of West
- 1:13Speaker 1: Virginia and certified in weapons.
- 1:16Speaker 2: Of mass destruction response. Yes, Doctor Mark Slaboy, All right,
- 1:27Speaker 2: welcome everyone, Welcome back to the Pain Pod. So here today,
- 1:32Speaker 2: on this episode of the Pain Pod, we're going to
- 1:35Speaker 2: dive into perhaps a new mini series. We're gonna call
- 1:38Speaker 2: it pain Pearls. Okay. A couple of months ago I
- 1:43Speaker 2: reached out on good old LinkedIn to the I guess
- 1:45Speaker 2: pain pod Nation or quite frankly anyone on the internet
- 1:48Speaker 2: right and was like, Hey, what are some of the
- 1:50Speaker 2: pearls that you all want to hear about? So some
- 1:53Speaker 2: of those you're gonna hear about right here, right now
- 1:55Speaker 2: in this episode. Others, well, we'll continue the series. That
- 2:00Speaker 2: being said, Hey, get out your seat and jump around.
- 2:04Speaker 2: But in the meantime, also stop and message me, whether
- 2:07Speaker 2: you go to pain guy dot us and message me
- 2:09Speaker 2: or message on LinkedIn or whatever you so choose, if
- 2:13Speaker 2: you're thinking of a pain pearl you're in or you
- 2:16Speaker 2: encounter a pain a patient and pain situation, or you
- 2:21Speaker 2: know you are the patient, or it's a family friend,
- 2:23Speaker 2: or you're the clinician or whatever, and it's just a conundrum,
- 2:27Speaker 2: you know, requiring a pearl. It's these little doses of
- 2:31Speaker 2: wisdom and experience and knowledge that could you help us
- 2:34Speaker 2: out with the trickiestiff scenarios. Hence, in the clinical world,
- 2:39Speaker 2: well we call those clinical pearls. Here today we call
- 2:41Speaker 2: them pain pearls. But if you want to contribute a
- 2:43Speaker 2: pain pearl situation, you don't necessarily need the answers. Reach out.
- 2:47Speaker 2: Let pain Guy know we'll make it happen, okay, because
- 2:50Speaker 2: we're going to intend to make this a whole little
- 2:52Speaker 2: mini series of pain pearls here on the Pain Pod.
- 2:55Speaker 2: So Chapter one, Part one, Episode one, you pick it.
- 2:59Speaker 2: I'll go with part one because well, why not have
- 3:01Speaker 2: the alliteration with the pas, right, So well, let's let's
- 3:05Speaker 2: come in hot. Okay, you know, one of the trickiest
- 3:08Speaker 2: situations out there. This is going to be a shout
- 3:11Speaker 2: out to not only the clinician side of the listening
- 3:14Speaker 2: audience here for pain POD, but also you know, patients
- 3:17Speaker 2: and pain as well too, and our family members are caregivers. Everybody,
- 3:21Speaker 2: right inherited patients or if you're digging the patient perspective,
- 3:26Speaker 2: packing up the bags and heading to someone else for help, right,
- 3:31Speaker 2: you know, gets in. You know, sometimes it's tricky situations.
- 3:33Speaker 2: Sometimes it's pretty straightforward. You know, a lot of times,
- 3:37Speaker 2: particularly even on the clinician side. You know, we can
- 3:40Speaker 2: inherit or receive or take over help for patients and pain.
- 3:45Speaker 2: And there might be things like hyper algesia, There may
- 3:49Speaker 2: be drug drug interactions, There may be questionable diagnoses. There
- 3:52Speaker 2: are you know, side effects of medications or laundry lists
- 3:56Speaker 2: of medications that we might be able to deprescribe along
- 3:58Speaker 2: the way or converse. Hey, maybe more is needed because
- 4:01Speaker 2: the list isn't even you know, past one or something,
- 4:05Speaker 2: you know, and there's a lot of things to go
- 4:07Speaker 2: around in those scenarios. You know, it typically reverts back
- 4:11Speaker 2: to good old opioid best practices. They're really controlled substance
- 4:15Speaker 2: best practices. Now, in previous episodes of the Pain Pod,
- 4:18Speaker 2: we've gone over some of those opioid best practices, you know,
- 4:21Speaker 2: things like you know, maybe even review of a prescription
- 4:24Speaker 2: drug mounitting Program PDMP. It's not the end all, folks,
- 4:27Speaker 2: It's one of the tools discussing the loxown or any
- 4:30Speaker 2: of the opioid new antagonists gott helmophene entering the ring
- 4:33Speaker 2: these days, Uh, the drug drig interactions, particularly when it's sedatives.
- 4:38Speaker 2: You know, we had an episode it feels like forever
- 4:40Speaker 2: ago on opioid interactions of you know, just going over
- 4:43Speaker 2: the what are the databases say? Right, it's not the
- 4:46Speaker 2: same wording when you you know, plug in different medications
- 4:49Speaker 2: three four different setative medications and seeing what the databases
- 4:53Speaker 2: say is relevant takes that expertise of a pharmacists in
- 4:58Speaker 2: the background and you know, clinic overall, you know, other
- 5:02Speaker 2: things like patient provider agreements or contracts, physical exams, I diagnosees,
- 5:07Speaker 2: you know, utilization of a diverse treatment plan. You know
- 5:11Speaker 2: here in a as a pharmacist, I mean we concentrate
- 5:13Speaker 2: certainly on pharmacological treatment options, but what about nonfarm and
- 5:17Speaker 2: when you're within the farm, there's different fields so opioids,
- 5:21Speaker 2: non opioids, fields of poppy, fields of cannabis. These are
- 5:28Speaker 2: all bigger picture topics, but you know things of you know,
- 5:31Speaker 2: going over with patients along the way. Well, what if we,
- 5:34Speaker 2: you know, are in a scenario, you know, in here
- 5:36Speaker 2: in a patient with a high risk opioid dosage. I'm
- 5:39Speaker 2: just gonna throw this one out there, say like oxycote,
- 5:42Speaker 2: we'll have IR and ER right, yeah, you know that
- 5:44Speaker 2: one two punch there, right to prevent pain and then
- 5:47Speaker 2: take care of any breakthrough along the way. It's like,
- 5:50Speaker 2: you know, anytime we see as needed in the SIG
- 5:52Speaker 2: the directions, it's like, well is that actually around the
- 5:54Speaker 2: clock or is it supposed to be as needed. That's
- 5:57Speaker 2: a conversation, you know, both for patients to have their
- 6:00Speaker 2: clinicians and clinicians to have with their patients. Right, Let's
- 6:04Speaker 2: say the patient's utilizing ox code on ER forty miligrams
- 6:09Speaker 2: twice a day, and then on the IR the immediate
- 6:11Speaker 2: release it's thirty miiligrams. We'll say four times a day, Okay,
- 6:16Speaker 2: I could go through all different cases, we can come
- 6:18Speaker 2: up with funky names and all that, but let's just
- 6:19Speaker 2: hone in on the math there, right, So oxy er
- 6:23Speaker 2: forty twice a day, that's eighty miligrams and then thirty
- 6:26Speaker 2: miligrams I are four times a day. That's one hundred
- 6:29Speaker 2: and twenty miligrams. I'm sure everbody's keeping up with the
- 6:32Speaker 2: eighty plus one twenty equals two hundred, right then you
- 6:35Speaker 2: got to multiply that out typically by the mm factor.
- 6:38Speaker 2: Generally accept it actually to be one point five. Not
- 6:41Speaker 2: that long ago, about a decade used to be one
- 6:44Speaker 2: and it became one point five right now. Of course,
- 6:48Speaker 2: we had a pain pot episode on the CDC guidelines
- 6:51Speaker 2: even you know, back in the day, the twenty sixteen
- 6:53Speaker 2: ones and then the new loss of the land being
- 6:55Speaker 2: the you know, overall updated CDC opiate guidelines, but generally
- 7:00Speaker 2: accepted be the hey, it's one point five. Lots more
- 7:03Speaker 2: discuss in that realm, but so that's you know, two
- 7:05Speaker 2: hundred times one and a half is of course three
- 7:06Speaker 2: hundred generally accepted now within the updated CDC opiod guidelines
- 7:12Speaker 2: and general best practices just be about a ten percent
- 7:15Speaker 2: reduction you can call it monthly or you know, always
- 7:19Speaker 2: going gradual as possible with getting the results. So that's
- 7:22Speaker 2: about thirty mms per day. Then you got to redivide
- 7:26Speaker 2: that back for the MM factor because if you're reduced
- 7:28Speaker 2: them by thirty mms, that's really twenty milligrams, right, because
- 7:32Speaker 2: it's the one point five factor. So in the big picture,
- 7:35Speaker 2: you know, starting with forty twice a day and thirty
- 7:37Speaker 2: four times a day, you're looking to go you know,
- 7:39Speaker 2: we typically go on the er side, So instead of
- 7:43Speaker 2: forty twice a day, you can make it thirty twice
- 7:45Speaker 2: a day and keep that IR thirty four times a
- 7:47Speaker 2: day as needed around just in case, right, But you
- 7:51Speaker 2: also want to evaluate the overall pay management scenario because
- 7:53Speaker 2: again this initial coming in hot case was an inherited
- 7:57Speaker 2: patent case with a lot more going on than just
- 7:59Speaker 2: the opio us, right, So we got to keep that
- 8:02Speaker 2: in mind. So where where do we you know, big
- 8:04Speaker 2: picture here, where do we go? Where do we start?
- 8:08Speaker 2: Let's take the patient journey? Okay, first, then they diagnosis side.
- 8:12Speaker 2: There's of course physical exam. Maybe we'll do some pearls
- 8:15Speaker 2: on that one next time. But I'm going to jump
- 8:17Speaker 2: into the radiology side. Okay, let's get let's put on
- 8:20Speaker 2: our lead. It's time for some lead, folks. Okay, disclaimer,
- 8:23Speaker 2: you don't actually have to put your lead on because
- 8:26Speaker 2: unless you're actually listening to this in an X ray room,
- 8:28Speaker 2: which some might question. But anyways, what about conflicting x rays.
- 8:33Speaker 2: We're a little pearl out there, right, you know, we
- 8:36Speaker 2: I'll oftentimes are treated like the law of the land
- 8:38Speaker 2: of like, hey, look at this objective. You know evidence
- 8:41Speaker 2: we have here, right, But there's instances few, but there's
- 8:45Speaker 2: instances where you know, us humans, our bodies, they're they're
- 8:48Speaker 2: wicked awesome. Right. You can have symptomatic perfection where you know,
- 8:53Speaker 2: the X ray is unremarkable, but the patient states on
- 8:56Speaker 2: going back pain, so you know it's symptomatic, but the
- 8:59Speaker 2: X rays quote unquote perfect. Right. Uh, where do we
- 9:03Speaker 2: go there? Right? Is somebody just making it up? Well,
- 9:08Speaker 2: I mean that's always possibility, but when someone's in pain,
- 9:11Speaker 2: we got to listen, right. Conversely, we could have the
- 9:14Speaker 2: asymptomatic chaos. You know, that's where the X ray X
- 9:17Speaker 2: ray would know multiple major spine concerns at the patient
- 9:21Speaker 2: sitting there twittering their thumbs perfectly fine, wondering why you're
- 9:23Speaker 2: asking questions about pain. I most would probably rather be
- 9:27Speaker 2: in the latter situation because it involves no pain. But
- 9:31Speaker 2: it's still you know, we we have to acknowledge that
- 9:34Speaker 2: that's a thing out there. Okay, that's that's one of
- 9:36Speaker 2: our first pearls here is that, you know, any one
- 9:40Speaker 2: tool that we utilize as clinicians, it is not the
- 9:44Speaker 2: law of the land. There, we're actually talking about the
- 9:47Speaker 2: law of the land, right all right, So patient journey,
- 9:51Speaker 2: we went over some diagnoses there. We well, pain scales.
- 9:53Speaker 2: That's so boy at at to get you. That'll get
- 9:57Speaker 2: you real quick, right, So we've got to have something,
- 9:59Speaker 2: got have something to help us with the diagnose side, right,
- 10:04Speaker 2: So you know, it brings up the idea of smart goals.
- 10:07Speaker 2: You know, even before utilizing pain skills, it is something
- 10:11Speaker 2: it's like that P one topic first year of pharmacy school, specific, measurable, achievable, relevant,
- 10:17Speaker 2: and timely smart that that acronym along the way, right,
- 10:22Speaker 2: So smart goals we're we're you know, it's like soft
- 10:24Speaker 2: skills in life really important, right, you know, are we
- 10:27Speaker 2: going to treat pain as the fifth vital sign that
- 10:29Speaker 2: got kind of kicked out the door. But what do
- 10:31Speaker 2: we ever want it to be? Zero? Right? The word analgesic,
- 10:35Speaker 2: it's derived from Greek to me without pain? Is that
- 10:38Speaker 2: really the goal? The goal is not always to eliminate
- 10:40Speaker 2: all pain, because it comes with its baggage, right, But
- 10:43Speaker 2: the goal is always to improve function and hopefully reduce
- 10:46Speaker 2: pain significantly if we can. Right. And that is a
- 10:50Speaker 2: compassionate way of going about things too, because we want to,
- 10:53Speaker 2: you know, make it so that folks can all of
- 10:56Speaker 2: us couldn't function and do you know, activities of daily living,
- 10:59Speaker 2: so on and so forth. Right, So pain scales though, Oh,
- 11:03Speaker 2: let's hash it out here. Folks, feel free to message
- 11:05Speaker 2: me sometime. What's your favorite response? I've got a few
- 11:08Speaker 2: of them. Hey, patients, how would you rape your pain?
- 11:11Speaker 2: One to ten? And I'm not necessarily the one asking
- 11:14Speaker 2: these questions because I like to ask intelligent questions, right,
- 11:17Speaker 2: one to ten, twenty? Hi, how would you rage pain? One? Ten? Yes?
- 11:22Speaker 2: I would rage pain one ten, thirteen. That doesn't sound lucky.
- 11:26Speaker 2: How'd rage pain one to ten? Two? And then we've
- 11:31Speaker 2: ever gotten that one? Well, you know, how would rage pain? Pain?
- 11:35Speaker 2: Guy in the er at the beginning of COVID pandemic
- 11:38Speaker 2: with nephrothiasis, kidney stone eight point five and ask silly questions.
- 11:42Speaker 2: I'm gonna give you silly answers. It's totally accounting for
- 11:45Speaker 2: broken bones, bear mullings, and childbirth half a point each,
- 11:49Speaker 2: So left them with eight point five. Well, else would
- 11:50Speaker 2: I be in an er on a Friday night at
- 11:52Speaker 2: the beginning of a pandemic? All right? That being said,
- 11:56Speaker 2: that was yours truly, not on the mic, but on
- 11:59Speaker 2: the journey. My favorite response from patient ever, ever, was
- 12:05Speaker 2: how would you reache pain? One to ten? Three point
- 12:08Speaker 2: one four? I didn't know if I wanted to shake
- 12:10Speaker 2: his hand or hug them or both or whatever. It's
- 12:13Speaker 2: pie never ending. So pain scales where we seem to
- 12:18Speaker 2: be knocking them right, but you know, is it a
- 12:21Speaker 2: necessary evil or is it you know, we got to
- 12:23Speaker 2: we have to have something to help us, right, so
- 12:26Speaker 2: we could break them down to there's ones for adults.
- 12:28Speaker 2: There's ones on the pediatric side. You know, on the
- 12:31Speaker 2: adult side, we've got numeric rating scale, visual analog scale,
- 12:36Speaker 2: nonverbal scales, behavioral pain scales. Even you know, if you're
- 12:40Speaker 2: if you're in a tricky situation, things like critical care
- 12:43Speaker 2: observation tools or seapot. One of the big go to
- 12:47Speaker 2: is really, of course, would be the d v PRS.
- 12:49Speaker 2: I'll come back to that in hot second or two.
- 12:51Speaker 2: On the pediatric side, we got a long list of
- 12:53Speaker 2: those too. We got the end pass cry is. That's
- 12:56Speaker 2: a famous one if pain scale were to be famous,
- 13:00Speaker 2: flak or even the revisors and chiops, the hung Baker
- 13:04Speaker 2: faces scale, and of the most basic things, of course,
- 13:06Speaker 2: because its face is so on and so forth, right,
- 13:08Speaker 2: but we do have that distinguishment. A couple real quick
- 13:11Speaker 2: and quick and easier ones per se would be the
- 13:14Speaker 2: PEG scale, going over pain intense three things pay intensity,
- 13:18Speaker 2: interference with enjoyment of life, so enjoyment's the E. Interference
- 13:22Speaker 2: with general activity general G is the G so peg
- 13:26Speaker 2: pain enjoyment general activity. There's also another one, great chronic
- 13:31Speaker 2: pain scale would be another one. It's like two questions
- 13:34Speaker 2: that'll that'll get the conversation going. But alas I gave
- 13:38Speaker 2: you the drum roll for the good old DVPRS, it
- 13:41Speaker 2: basically combines so in a way, our taxpayer dollars paid
- 13:44Speaker 2: for this because it's from the Department of Defense and Veterans, Right,
- 13:48Speaker 2: little combo action there it's got the faces, it's got
- 13:51Speaker 2: the colors, it's got the numbers, it's got the descriptions,
- 13:53Speaker 2: it's got it all. But that's still basic pain scales. However,
- 13:58Speaker 2: the bottom portion or the back of the age, depending
- 14:00Speaker 2: on how you print it out. If you print it out,
- 14:03Speaker 2: it's got four additional questions rate in zero to ten
- 14:05Speaker 2: on activity, sleep, mood, and stress by Gully. We may,
- 14:10Speaker 2: as clinicians, may not be able to change someone's pain
- 14:12Speaker 2: rating of seven sadly, ever, but we could certainly attempt
- 14:17Speaker 2: to help with activity, sleep, mood, and stress to help
- 14:20Speaker 2: improve one's life, and help with perspectives along the way too.
- 14:24Speaker 2: And the reality. Right, speaking of reality, here's our next pearl.
- 14:30Speaker 2: Someone who, again, whether clinician or a patient, I've tried everything.
- 14:35Speaker 2: It's like, I mean, what's the natural knee jerk response?
- 14:38Speaker 2: Really everything? Not to sound like doctor Evil from Aston
- 14:43Speaker 2: Powers there, but we tried one million different treatment options.
- 14:49Speaker 2: M interesting, and again this is on the positive side
- 14:53Speaker 2: of you know what options are really there? Right? Relatively
- 14:58Speaker 2: limited pain management, but also so expansive. Cake you eat
- 15:01Speaker 2: it too, right, got the non pharmacological options. Dozens usually
- 15:06Speaker 2: recommend to group them into active and passive. Does a
- 15:09Speaker 2: patient want to be involved or those a patient want
- 15:11Speaker 2: you to take care of him or her? Right, So
- 15:14Speaker 2: lots of different options there. Overall, there's, of course, our
- 15:18Speaker 2: friends in the interventional realm. I usually say you got
- 15:20Speaker 2: the darts, lasers, tasers, and pumps. Oh, some of them
- 15:23Speaker 2: would kick me in the kidney for that, those simplification things,
- 15:27Speaker 2: but some would say, yep, you nailed it as well.
- 15:30Speaker 2: Nerve blocks, injections, radio frequency ablasion, neurostimulation, interthecal and then
- 15:35Speaker 2: also orthone spine surgery afterwards or along the way as well.
- 15:40Speaker 2: We also have within our own realm and pharmacy the
- 15:43Speaker 2: pharmacological treatments. You got topicals, you got TCAs, you got snriys,
- 15:48Speaker 2: you got SSRIs even n SAIDs citymnifin atypically adepressants, opioids,
- 15:55Speaker 2: perhaps even cannabinoids. Will see how the future goes, right,
- 15:58Speaker 2: there's a lot. And one of the things that gets
- 16:01Speaker 2: lost in translation is it's not one at a time,
- 16:04Speaker 2: make the checkbox. It's different combinations too, right, So if
- 16:08Speaker 2: you have like ten options, it's not like you know,
- 16:10Speaker 2: it's more of the ten times nine times eight. Keep
- 16:13Speaker 2: going down the scale. That's how many options there are,
- 16:15Speaker 2: and you end up with millions. Right. The art of
- 16:19Speaker 2: it all is figuring out what is best for each
- 16:22Speaker 2: patient based on guidelines. I got a plethora of paying
- 16:25Speaker 2: guidelines available in payingguid dot us under the resources, and
- 16:28Speaker 2: there's so many more out there as well too, So
- 16:31Speaker 2: lots and lots of options. That's the big thing, all right,
- 16:34Speaker 2: patient journey, back to the patient journey. So you know,
- 16:36Speaker 2: after that whole diagnose section there, right, then what about
- 16:40Speaker 2: risk assessment and mitigation along the way? Right, So we've
- 16:44Speaker 2: got to say we're going to the opioid realm. There's
- 16:46Speaker 2: different opioid risk screenings. I usually recommend two questions to
- 16:50Speaker 2: figure out which of the many are we going to utilize? Right,
- 16:55Speaker 2: So first question is are you going to do it?
- 16:56Speaker 2: Or is patient going to do? Is a clinician going
- 16:58Speaker 2: to administer these screening or is the patient can do
- 17:00Speaker 2: it on their own, you know, perhaps on a electronic
- 17:04Speaker 2: tablet or part of the four hundred pieces of paper
- 17:06Speaker 2: we give them a while checking in, right. And then
- 17:09Speaker 2: the second question, other than you know, patient or provider,
- 17:12Speaker 2: is is the patient opiated NIAVOR experienced picture A. It's
- 17:16Speaker 2: like the genetics back in the day with the Darwin
- 17:19Speaker 2: and the turtles and the island and all that stuff.
- 17:21Speaker 2: A four box are there, right? Four box a little chart,
- 17:24Speaker 2: and when you answer the two questions for the rose
- 17:26Speaker 2: and the columns, you land on narrowing it down to
- 17:29Speaker 2: which of the opiated rists screenings is a dash soap
- 17:32Speaker 2: or a TP duke, com PMQ dire just using all
- 17:36Speaker 2: the shortened names. Of course, one I'd usually highlight would
- 17:40Speaker 2: be the opiod rist tool, you know, sure, certainly a
- 17:44Speaker 2: shout out there to doctor Webster, Lynn and team of
- 17:48Speaker 2: course did a lot back in the day and making
- 17:50Speaker 2: that one. There's been a revision of course, there's the
- 17:53Speaker 2: revised or it's really called the O R T s
- 17:55Speaker 2: U D, which removes one precarious question. But when navigating
- 18:00Speaker 2: the opiated risk tool, a lot of the times we
- 18:02Speaker 2: already as clinicians we have the answers to the questions
- 18:06Speaker 2: because we know our patients, right like is there a
- 18:08Speaker 2: family history of addiction? Is there a personal history of addiction?
- 18:12Speaker 2: What's the patient's age sixteen to forty five comes to mind?
- 18:15Speaker 2: For you know, the screening, any psychological diseases, conditions, so
- 18:19Speaker 2: on and so forth, and then what's in the OORT
- 18:22Speaker 2: is a question on a history of pre adolescent sexual abuse.
- 18:26Speaker 2: That's a tough question to ask, right. A lot of
- 18:28Speaker 2: patients will appreciate and know that you care when asking that.
- 18:32Speaker 2: But theort SUD removes that question keeps everything else intact
- 18:36Speaker 2: along the way. Okay, you know what I would like
- 18:39Speaker 2: to throw out there? And again, folks, this is conversational.
- 18:42Speaker 2: We're on a podcast. We're not on a New England
- 18:45Speaker 2: journal or jamming here. But you know the old potato
- 18:48Speaker 2: chip ad I believe it was with Lai's chips. Bet
- 18:51Speaker 2: you can't eat just one. If you're like me, you
- 18:54Speaker 2: can't take them up on that offer because I find
- 18:57Speaker 2: it very hard to eat just one. Right. If I
- 18:59Speaker 2: like some thing, I probably want more than one. Unless
- 19:02Speaker 2: it's like a four pound steak, then that might get you. Right.
- 19:06Speaker 2: But you know, if someone's answering that, I'm not saying.
- 19:09Speaker 2: In patient practice, we're not there yet. But conversationally, it's
- 19:14Speaker 2: that mindset of you know, if it's hard to say,
- 19:17Speaker 2: you know, no to more of something that's enjoyable, Like
- 19:20Speaker 2: if someone had a controlled substance and got euphoria from it,
- 19:23Speaker 2: then that could be a screening thing. There as well too.
- 19:26Speaker 2: Just again conversational, you know, for us here along the
- 19:29Speaker 2: way when someone does you know, an opiator of screening
- 19:32Speaker 2: and there's you know, higher risk, you know, what do
- 19:34Speaker 2: we do? You know, we do those best practices, you
- 19:36Speaker 2: know PDMP. You're a drink monitoring. There's abuse to tern
- 19:40Speaker 2: formulation opioids that are out there. They aim to prevent
- 19:43Speaker 2: the transition from a prescription opioid to heroin or fentanyl
- 19:48Speaker 2: these days. Kind of hard to get heroin these days
- 19:51Speaker 2: might be labeled that, but probably fentanyl or its analogs. Right.
- 19:55Speaker 2: But we've got typically the four options. There's one hydrocode
- 19:58Speaker 2: on product I sing uh, and then there's the three
- 20:01Speaker 2: oxycodone products. Two of them are er one's the E
- 20:05Speaker 2: or tablet. Of course you know of oxycon unless you've
- 20:08Speaker 2: been under a rock for decades. Uh. Then there's the
- 20:10Speaker 2: E R capsule, the xtams at R, and then there's
- 20:13Speaker 2: the relatively newer to the market I are tablet roxy bond.
- 20:18Speaker 2: Kind of interesting when you think of an abuse to
- 20:20Speaker 2: turn formulation IR formulation, because it's meant to prevent the
- 20:24Speaker 2: you know, deter the abuse abuse to turn formulation ad
- 20:29Speaker 2: F opioid. But you need, you know, that acute use
- 20:33Speaker 2: along the way. It's philosophically a conundrum, but that's what
- 20:37Speaker 2: the things were approved for along the way there too,
- 20:40Speaker 2: So you know, speaking of choosing you know which when
- 20:44Speaker 2: the situation requires it and it's time to utilize a
- 20:50Speaker 2: prescription opioid, which one. I asked that question on LinkedIn gosh,
- 20:54Speaker 2: probably a year ago, and boy did it flop or
- 20:58Speaker 2: the responses flop. Not not throwing any shade here, folks,
- 21:02Speaker 2: but we got to think about it, like if you
- 21:05Speaker 2: know it certainly is depends on the patient scenario, right,
- 21:08Speaker 2: But in the end, if you're given a patient scenario
- 21:10Speaker 2: of a otherwise healthy twenty some thirty some year old,
- 21:16Speaker 2: we'll see a male patient. You know, again otherwise healthy
- 21:20Speaker 2: just has now has chronic lower back pain and has
- 21:23Speaker 2: gotten to the point of utilization of a prescription opioid.
- 21:26Speaker 2: Which one, that's the scenario. I want you to think
- 21:29Speaker 2: about that, right, because it does depend on the scenario.
- 21:32Speaker 2: But at what point, as clinicians can we not be
- 21:35Speaker 2: comfortable with saying this is the go to in certain
- 21:38Speaker 2: in majority of situations. Right, We've got a laundry list
- 21:42Speaker 2: of options when it comes to prescription opioids. I mean
- 21:45Speaker 2: you got your ones that are a little bit more
- 21:46Speaker 2: on the end patient side, or at least in a
- 21:48Speaker 2: situationd scenario like that, like you know, soup fentanyl or
- 21:51Speaker 2: a little serodine. But otherwise we got you know, bens
- 21:55Speaker 2: hydro code on coding, and we got dihydro coding, hydro
- 21:58Speaker 2: code on, hydromorphon, morphine, technically opium oxycode on, oxymorphone, betrophenol, penthazesan, fentyl.
- 22:07Speaker 2: We got my parodine, we got buchan orphine, love orphanol, methadone,
- 22:11Speaker 2: to penthodol, tramadol. That's a lot, right. You know, no
- 22:16Speaker 2: scenario is gonna be throwing darts, so you know it
- 22:18Speaker 2: begs that question. And please please please let me throw
- 22:22Speaker 2: me a message on LinkedIn or what what's you know,
- 22:24Speaker 2: what's your go to along the way? Right, We've done
- 22:28Speaker 2: this even with insets. There was a time I helped
- 22:32Speaker 2: to devise this thing of inset selection factors a Baker's
- 22:35Speaker 2: dozen meaning thirteen. Of course, you know, is acuter chronic pain.
- 22:38Speaker 2: What's the other conditions or situations? Is there a formulation
- 22:41Speaker 2: preference any cardio or GI concerns palm concerns, real art
- 22:46Speaker 2: pathic concerns, dosas, frequency preference. They're procedures like interventional side
- 22:51Speaker 2: we have discontinue the inset sometimes drug drig interactions. You
- 22:54Speaker 2: see your prescription cost concerns, age, child or adult pregnancy.
- 22:58Speaker 2: Those are all things that go into play. And you're
- 23:00Speaker 2: selecting an insight, so you know, same thing can go
- 23:03Speaker 2: for an opioid. But what's you know when that's all,
- 23:05Speaker 2: when the questions are only answered and the smoke clears,
- 23:08Speaker 2: what do you choose? Right? All right? So once in
- 23:11Speaker 2: an opioid is selected, where do you begin with the dosage? Right?
- 23:15Speaker 2: That's a very good question. I draw off of that
- 23:19Speaker 2: again the most recent CDC opioid guideline update, and the
- 23:23Speaker 2: over idea is to start logo slow, and they actually
- 23:25Speaker 2: articulated and stated a place to start for opioid naive
- 23:29Speaker 2: starting doses. It was stayed in that guideline to be
- 23:32Speaker 2: five to ten mmes for a single dose, or could
- 23:35Speaker 2: be worded as twenty to thirty mms per day. So
- 23:38Speaker 2: there we have it. That's a starting place, right, It's
- 23:41Speaker 2: not like we're far off before that would make it
- 23:43Speaker 2: something like hydrocnonocenam I from five three twenty five. It
- 23:48Speaker 2: wouldn't make it oxy codone are ten milligrams because that
- 23:53Speaker 2: would be fifteen, which is over the five to ten, right,
- 23:56Speaker 2: So you know, there's we got to keep that in
- 23:59Speaker 2: mind overall as well. You know, here we are, we
- 24:02Speaker 2: continually talk about these mms, right, more female gram equivalent factors.
- 24:06Speaker 2: A couple of pearls in that realm too, So that
- 24:08Speaker 2: most recent CDC guideline update there for you know, the
- 24:11Speaker 2: OPII guideline update had three MM updates. The hydromorphone meem
- 24:16Speaker 2: factor shifted from a four to a five, methodone went
- 24:19Speaker 2: from calculus to four point seven, and tram it all
- 24:22Speaker 2: went from zero point one to zero point two. It
- 24:24Speaker 2: sounds like it's barely in the drinking water of our country,
- 24:26Speaker 2: but it's not. But you know when you multiply it
- 24:29Speaker 2: by one hundred mili gramd pill that escalates quickly. Right,
- 24:31Speaker 2: But there's you the pearl here is you know, there's
- 24:34Speaker 2: limitations when it comes to utilization of mmes. I think
- 24:38Speaker 2: we will passed everyone admitting and realizing and being aware
- 24:41Speaker 2: of that in those CDC guidelines, the twenty twenty two update.
- 24:46Speaker 2: They even stated in a public health sense because it
- 24:49Speaker 2: is the CDC that MME factors are only estimates, shouldn't
- 24:52Speaker 2: use them for opioid use disorder. They also said you
- 24:55Speaker 2: shouldn't use it for opioid rotation, but well if you're not,
- 24:58Speaker 2: then what do you useing them? Or for comparative right?
- 25:01Speaker 2: They said be careful with methadone and transdermal fetanyl and
- 25:05Speaker 2: mute and orphye wasn't included because of the partial mewoagonism
- 25:08Speaker 2: and the ceiling effects and stigma along the way as
- 25:10Speaker 2: well too. You know, well before that there was many
- 25:13Speaker 2: of us in the pain space all share mind, but
- 25:16Speaker 2: you know had all the limitations. Well, first up, hey,
- 25:19Speaker 2: we're human. We're all different, right, so we got to
- 25:21Speaker 2: take that into account age weight, high genetics and padic
- 25:23Speaker 2: agrena function medications that were realized we're all different, right again,
- 25:27Speaker 2: the conversion estimates. The dose response curve is a big one,
- 25:31Speaker 2: you know, is it a value? Every response is going
- 25:34Speaker 2: to have a different dose response curve as a possibility.
- 25:37Speaker 2: So are we analyzing when looking at enemies the resptory
- 25:40Speaker 2: depression risk or the analgesic effects which one probably not
- 25:44Speaker 2: the same. Yeah, we typically go with it looking at
- 25:48Speaker 2: resptory depression risks, but then utilizing in an analgesic sense. Right, interesting,
- 25:54Speaker 2: there's also formulation by all availability variability, say that one
- 25:57Speaker 2: three times we got mixed action opioids a good old
- 25:59Speaker 2: friend of things like tapentadol, trimatol, even methodone you name it,
- 26:03Speaker 2: where they work in different ways in addition to being
- 26:05Speaker 2: an opioid agonist. You know there too, So which one
- 26:09Speaker 2: is it? Is it an oorrip an effort effect or
- 26:11Speaker 2: the immute effect? There's tolerance. You know, someone taking twenty
- 26:16Speaker 2: methodone is not the same as a new patient take
- 26:17Speaker 2: in one methodone tablet ten miligrams, Right, it's different. And
- 26:24Speaker 2: then there's all their variabilities with methodone and transdormal fetanel
- 26:27Speaker 2: along the way. But big pictures a lot of limitations. Right.
- 26:29Speaker 2: In fact, here's a double pearl for you. New opioid
- 26:34Speaker 2: medication is coming to market. How do they figure out
- 26:37Speaker 2: the MME? Is it receptor affinity like the magnetism of
- 26:40Speaker 2: the receptor. Is it a trial it's head to head
- 26:42Speaker 2: with morphine? There's it a trialo head to head with
- 26:45Speaker 2: a similar structure opoioid. Well, what about if it's mixed action?
- 26:49Speaker 2: What about if it has different formulations. A lot of
- 26:52Speaker 2: questions there, quite the conundrum. Answers will be had, but
- 26:56Speaker 2: quite the conundrum when you think about it. Right, you know,
- 27:00Speaker 2: here's another conundrum by jump out of your seat if
- 27:04Speaker 2: you've ever been perplexed with a patient reporting or a
- 27:07Speaker 2: philo clinician reporting for a patient that they have an
- 27:10Speaker 2: opioid allergy and you're like, was it? Because you know,
- 27:14Speaker 2: it's not being doubtful, it's just questioning the establishment processes
- 27:19Speaker 2: of allergy. If you hitched, right, Yeah, it's different. Anaphylexis
- 27:24Speaker 2: versus histamine release is a big, big thing. You know,
- 27:27Speaker 2: it's expected as a potential side effect to have itching
- 27:31Speaker 2: based on histamine release when a prescription opioid is utilized.
- 27:35Speaker 2: And we got to remember that OPII priitis is a thing.
- 27:38Speaker 2: It's a potential side effect along the way. So yes,
- 27:41Speaker 2: it's certainly a good thing to ask those questions along
- 27:43Speaker 2: the way and in fact and form our patients that hey,
- 27:46Speaker 2: this is a possible side effect, so that somebody's not
- 27:49Speaker 2: all worried and going to urgent care thinking they stepped
- 27:51Speaker 2: in poison ivy because they just started an opioid during
- 27:53Speaker 2: the summer when they were doing some weed whacking out
- 27:55Speaker 2: in the back. Right, good golly. So that that's you know,
- 27:59Speaker 2: another pearl, another idea here for us. All right, we're
- 28:04Speaker 2: two next folks. What's our next pearl? Here's one. This
- 28:07Speaker 2: will help particularly our new practitioners with the logxams or
- 28:11Speaker 2: if you're changing a state as well. People do move right,
- 28:14Speaker 2: fere set versus fur and all control or not? The
- 28:18Speaker 2: question remains, right, Well, it gets tricky. So fur a set,
- 28:25Speaker 2: you know, ceda minifin betalbot all in caffeine. Right, that's
- 28:30Speaker 2: and then of course you have the ones with codeine
- 28:32Speaker 2: along the way. So there was a there was an
- 28:34Speaker 2: old formulation and now there's a newer formulation. It didn't
- 28:37Speaker 2: happened yesterday. It's been a while. They basically changed a
- 28:40Speaker 2: whopping twenty five milligram decrease in the dose of a cedamnifin. Right,
- 28:45Speaker 2: But with that, since the controlled substance status of that
- 28:48Speaker 2: particular type of medicine is a ratio based thing, it's
- 28:51Speaker 2: multiple ingredients. Fear a sets is not a federal controlled substance. Okay, However,
- 28:58Speaker 2: there are states that classify is a controlled substance Class three.
- 29:02Speaker 2: To my knowledge, at this moment, that would be Georgia, Illinois, Maryland,
- 29:05Speaker 2: New Mexico, Rhode Island, Utah, and my own wild and
- 29:08Speaker 2: wonderful West Virginia. Okay. Conversely, there's fur in all, which
- 29:13Speaker 2: is aspirin but talbotol and caffeine and of course could
- 29:18Speaker 2: have codeine added. Furinol is actually a controlled substance Class
- 29:23Speaker 2: three on the federal level, so we don't have to
- 29:24Speaker 2: worry about the ratios. We don't have to worry about
- 29:26Speaker 2: which state. It's just fur and al is fear and
- 29:29Speaker 2: all always a control. Fear in always a control, right,
- 29:34Speaker 2: f you're a set. We got to figure out where
- 29:36Speaker 2: we are, right. So there's a little pearl for hopefully,
- 29:40Speaker 2: Oh I hope that's the one question that makes somebody
- 29:43Speaker 2: pass right as far as they're MPGe as the only
- 29:47Speaker 2: healthcare profession with a loxam pharmacy, good, bad, you name it.
- 29:52Speaker 2: That could be a whole other episode. Well, since we're
- 29:55Speaker 2: in the law realm here, let's all we opened up
- 29:57Speaker 2: the can. What about oxycon? And we're talking about that
- 30:00Speaker 2: the patient earlier to oxycode on R right, So if
- 30:02Speaker 2: someone has a prescription for oxycon, can oxycode on R
- 30:05Speaker 2: be substituted. It sounds like a silly question, but then
- 30:08Speaker 2: you dive a little bit deeper. Right, so generic versions
- 30:12Speaker 2: did show equivalence. Yet the Orange Book rating is NR
- 30:15Speaker 2: as in not rated, right as in not ab rated.
- 30:20Speaker 2: So another one where it depends on the state you're in.
- 30:23Speaker 2: There's about about one third to a half of states
- 30:27Speaker 2: that do not follow Orange Book, so you can substitute
- 30:31Speaker 2: oxicode on R for oxy coon. Then there's about a
- 30:34Speaker 2: half to two thirds of the states that they do
- 30:37Speaker 2: follow the Orange Book, so you cannot substitute oxy code
- 30:40Speaker 2: on er for oxycon. Okay, that's a tricky one prime
- 30:45Speaker 2: for something like an exam, but I don't believe it
- 30:48Speaker 2: actually tends to go in that realm anywhere recently. But
- 30:51Speaker 2: you know, there we go. So all right, all this
- 30:55Speaker 2: loss probably caused us some pain. You know what else
- 30:57Speaker 2: can actually cause pain? Opioids? What? Yeah, one of the
- 31:03Speaker 2: potential side effects. It's on the pis folks. You can
- 31:06Speaker 2: check them out. They're electronic these days too. As a
- 31:09Speaker 2: potential again this is not always, but a potential side
- 31:12Speaker 2: effect of opioids is neuralgia kind of otherwise known as
- 31:16Speaker 2: hyper algesia, which you know there's a difference there. To
- 31:20Speaker 2: explain hyper alges it's good to you know, put it
- 31:22Speaker 2: alongside tolerance. Tolerance means you would need to increase the
- 31:26Speaker 2: dose to get the same effects as in the past.
- 31:28Speaker 2: Hyperlges is an increased pain response to something that is
- 31:32Speaker 2: typically you know, painful, but you know, like paper cup
- 31:35Speaker 2: and it feels like you lost your leg. That's an
- 31:38Speaker 2: extreme version of hypergesia. What's one of the treatment potentials
- 31:41Speaker 2: for hyper algesia, You decrease the dose. That's probably one
- 31:45Speaker 2: of the hardest things to explain to a patient or
- 31:48Speaker 2: a fellow condition ever, you want me to decrease the
- 31:51Speaker 2: dose and expect to get more pain relief. Yeah, all right,
- 31:55Speaker 2: So let's dive deeper into that. So you know, first
- 31:57Speaker 2: you always want to you know, reevaluate the open would
- 32:00Speaker 2: use selection dosage, you know what's needed along the way,
- 32:03Speaker 2: and there's the potential to decrease the opioid dose. There
- 32:06Speaker 2: are studies out there that for opioid induce hyper algesy.
- 32:09Speaker 2: You could utilize gabapentin, be panorphine, or even methodone, so
- 32:14Speaker 2: you know those are out there, but typically it's really
- 32:17Speaker 2: starting with just decreasing the dose of the opioid. So
- 32:20Speaker 2: you know, I threw out that idea there of methodone
- 32:22Speaker 2: ten miligrams with a patient using twenty some of them earlier.
- 32:25Speaker 2: Let's let's say a patient's utilizing twenty seven tablets daily.
- 32:29Speaker 2: We'll say it's nine of the ten miligrams three times
- 32:31Speaker 2: a day, but we'll just say twenty seven tablet daily.
- 32:33Speaker 2: Right now, you're like, if you're on a treadmill, you just,
- 32:35Speaker 2: oh my goodness, don't don't hould off the treadmill. And
- 32:38Speaker 2: if you're driving, folks, pay attention to the road too.
- 32:40Speaker 2: But yes, there's a world out there and we're all human, right,
- 32:44Speaker 2: patient utilizing twenty seven methodon ten miligrams a day so
- 32:48Speaker 2: reporting more pain, do you increase to twenty eight a
- 32:51Speaker 2: day as the time for reevaluation might not be in
- 32:55Speaker 2: a reality there? Or do you discuss the likelihood of
- 32:58Speaker 2: hyper algesia and you know, possibly need to reduce the dose? Right,
- 33:03Speaker 2: that's that's a prol and a half. How would you
- 33:05Speaker 2: go about the dosage reduction? Well, ten tablets or ten
- 33:10Speaker 2: milligram tablets twenty seven a day, that's two hundred and
- 33:12Speaker 2: seventy milligrams of methadone. The mm factor is magically four
- 33:16Speaker 2: point seven. Now I'll do the math. It's twelve hundred
- 33:19Speaker 2: and sixty nine MMIs per day. Ten percent of that
- 33:22Speaker 2: for a gradual monthly taper will give you about one
- 33:24Speaker 2: hundred and twenty seven mms per day. Divide that by
- 33:28Speaker 2: like what's a tablet, So ten milligrams times four point
- 33:31Speaker 2: seven as the factor. At the bottom line is you
- 33:34Speaker 2: get about two point seven tablets per day. So if
- 33:36Speaker 2: you want to, you know, decrease it by about three
- 33:39Speaker 2: two to three tablet depending on a conservative or not
- 33:42Speaker 2: per day. That would be the gradual opioid tapering. And
- 33:46Speaker 2: then you got to kind of hit it home with
- 33:47Speaker 2: the patient too, if well, maybe just one tablet would
- 33:49Speaker 2: be fine as a reduction. See how things go along
- 33:52Speaker 2: the way. Math matters, But we also have to make
- 33:55Speaker 2: things clinically appropriate along the way, because in these cases
- 33:58Speaker 2: it's like we have to have a talk with the
- 34:00Speaker 2: opiot and say, you know what you're doing, great, just
- 34:01Speaker 2: not at pain. Definitely not at pain when it comes
- 34:03Speaker 2: to opioid induced hyper algesia. You know another clinical conundrum,
- 34:08Speaker 2: we'll call it a pearl. It would be a patient
- 34:10Speaker 2: with opioid addiction OUD and acute pain. Something happens, you know,
- 34:16Speaker 2: whether it what's post surgery, broken leg, you name it.
- 34:20Speaker 2: How do we go about that? Well, there's a lot
- 34:22Speaker 2: of chatter out there of all, you know, do you
- 34:24Speaker 2: just increase the bupnorphind dose maybe one to two milligrams,
- 34:28Speaker 2: you know, every so many hours throughout the day to
- 34:31Speaker 2: address that. That's certainly an option. Another option could be
- 34:35Speaker 2: the lipophilic opioids, your higher octane things. Of course, of course,
- 34:39Speaker 2: then they're going to be crossing the blood brain barrier,
- 34:42Speaker 2: things like fetnyl hydromorphone. And by now you're thinking, what
- 34:45Speaker 2: using fetnyl in a patient with opioid addiction. Well, again,
- 34:50Speaker 2: you know, it depends on the setting as well too.
- 34:53Speaker 2: Sitting in a gurney, in an er or in a
- 34:55Speaker 2: hospital is different than ambulatory. Right, So there's a lot
- 35:00Speaker 2: going on when it comes to the BUEP and orphine
- 35:01Speaker 2: pearls along the way. So you know, let's do a
- 35:05Speaker 2: couple more. All right, what about inductions? Oh, my goodness,
- 35:08Speaker 2: BUP and orphine inductions. So we have the traditional examples
- 35:12Speaker 2: and then the microdosing examples more current to this day.
- 35:17Speaker 2: So when the medications were first approved What was utilized
- 35:21Speaker 2: as the you know, induction doses was the concept of
- 35:24Speaker 2: waiting for the patient to be within withdrawal and then
- 35:27Speaker 2: starting the BUEP and orphane doses. You know, maybe hindsight
- 35:30Speaker 2: is twenty twenty, but boy, that doesn't sound too compassionate
- 35:35Speaker 2: at all. Good sir, ma'am, you've been trying to avoid
- 35:39Speaker 2: withdrawal for a good while now, so we're gonna let
- 35:41Speaker 2: you go into withdrawal and then we'll start taking care
- 35:43Speaker 2: of you. That's that's the traditional way now. Microdosing is saying, hey,
- 35:49Speaker 2: you know, take something like and there's different examples out there, folks,
- 35:52Speaker 2: but a half a milligram once a day, and then
- 35:54Speaker 2: twice a day, and then one milligram twice a day,
- 35:56Speaker 2: increasing a milligram you know dosage, you know, twice today
- 36:00Speaker 2: for a couple of days. Usually within a week you
- 36:02Speaker 2: can get up to about twelve miligrams. Again, there's different
- 36:05Speaker 2: examples out there for microdosing, but it's starting really really
- 36:08Speaker 2: low and going slow along the way. The idea is
- 36:11Speaker 2: to avoid the patient experiencing withdrawal. No one wants to
- 36:15Speaker 2: experience withdrawal. I hear, it's terrible, So why would we
- 36:19Speaker 2: want our patients to go that route. Now, microdosing might
- 36:22Speaker 2: not work out in every situation, of course, but you
- 36:25Speaker 2: know that's that's where we're headed these days along the way. Right.
- 36:29Speaker 2: All right, one more thing here, I think you know
- 36:32Speaker 2: we'd be remiss we opened up the can of bub
- 36:35Speaker 2: and orphine here, you know, films or tablets of course,
- 36:38Speaker 2: or injection. You know what about duration? And here we're
- 36:43Speaker 2: going to jump into the realm of opioid used disorder,
- 36:45Speaker 2: opioid addiction. Right, what's the minimum treatment? If that's not
- 36:50Speaker 2: a conundrum that's out there that sparks conversation like no other.
- 36:54Speaker 2: So I came across my my, I'll say, good buddy,
- 36:58Speaker 2: Jake Nichols, fellow pharmacist, and sure that I'm positive that
- 37:01Speaker 2: many of you know him. Well guess what. He was
- 37:04Speaker 2: on an episode of the Pain Pod back in the day,
- 37:05Speaker 2: So feel free to check that episode out. I highly
- 37:08Speaker 2: recommend it. But anyways, he actually shared this one time.
- 37:12Speaker 2: I sat through his presentations. He did it for a
- 37:14Speaker 2: state association in well to one for West Virginia, and
- 37:17Speaker 2: I was like, oh, finally got a resource for this.
- 37:19Speaker 2: So the idea here was, you know, what's what's the
- 37:23Speaker 2: percent of sustaining absence through the years to find you know,
- 37:28Speaker 2: a proverbial minimum MOUD treatment timeframe, right, medications for ape
- 37:33Speaker 2: use disorder. We're typically talking about pnorphine these days. You know,
- 37:37Speaker 2: only about a third of the time when you're talking
- 37:39Speaker 2: within you know, a year, that delbows to about two
- 37:42Speaker 2: thirds of the time when it's one to three years.
- 37:44Speaker 2: When you go above three years, like three to five
- 37:46Speaker 2: or five, you start looking at about an eighty six
- 37:49Speaker 2: percent according to one reference, I'll share it in the notes.
- 37:52Speaker 2: That's a big difference. Eighty six percent success compared to
- 37:56Speaker 2: thirty six percent. I mean, you can ask a kindergartener
- 38:00Speaker 2: and they'll get that one right, right. So you know,
- 38:04Speaker 2: maybe we're looking at multiple years as far as a minimum,
- 38:07Speaker 2: but we also have to balance that with it might
- 38:09Speaker 2: be just ongoing maintenance, right, just like blood pressure, just
- 38:14Speaker 2: like everything else along the way. Right, We got to
- 38:18Speaker 2: keep that into account there as well too. But you know,
- 38:20Speaker 2: there's a lot of personal facts out there. My sister
- 38:25Speaker 2: in law, Elizabeth, you know, homage tour there, as far
- 38:29Speaker 2: as I know, in our family, came up with that
- 38:31Speaker 2: term personal fact of it. It's another word for opinion
- 38:34Speaker 2: of the well, you know, we have our opinions, whether
- 38:36Speaker 2: they're personal or professional or both. But you know, we
- 38:39Speaker 2: got to look at the data along the way, and
- 38:41Speaker 2: we got to look for compassionate patient care along the
- 38:43Speaker 2: way as well too. So all right, so when it
- 38:46Speaker 2: comes to our discussion here on pain pearls, this will
- 38:51Speaker 2: be part one, Chapter one, episode one. It's gonna be
- 38:53Speaker 2: a little mini series, you know. Throughout the ages here.
- 38:58Speaker 2: I want to hear from you, though, so please please
- 39:00Speaker 2: message me about new pain pearls so we can get
- 39:02Speaker 2: more information out there. No worries. I'll give you the credit.
- 39:05Speaker 2: It's all good, you know. We want to you know,
- 39:08Speaker 2: get names out there of course too, and you know,
- 39:11Speaker 2: expand everyone's bandwidth. But I hope this brief discussion on
- 39:15Speaker 2: pain pearls it's part one of many folks, you know,
- 39:18Speaker 2: really stimulated your thought, kept you on the edge of
- 39:20Speaker 2: the seat, or kept your running if you're working out right.
- 39:23Speaker 2: But you know, we'll have more of this, but hopefully
- 39:27Speaker 2: this helps, you know, both in the patient side of
- 39:30Speaker 2: the clinician side, everyone who could potentially be listening, because
- 39:33Speaker 2: in the end, we want to provide the best patient
- 39:35Speaker 2: care possible. We want to experience the best patient care possible, right,
- 39:41Speaker 2: And it's not just practicing at the top of the licenses,
- 39:43Speaker 2: and it's it's much more than that. It's taking care
- 39:45Speaker 2: of each other along the way, right. So I hope
- 39:48Speaker 2: you enjoyed this pain Pearls episode here on the Pain Pod,
- 39:51Speaker 2: and I certainly welcome you back to well all the
- 39:54Speaker 2: previous episodes of the Pain Pod, but of course our
- 39:56Speaker 2: next episode of the Pain Pod along the way, so
- 39:59Speaker 2: pain pod Nation. I thank you as always and I
- 40:02Speaker 2: will always wish you a great day every day.
- 40:08Speaker 1: If you'd like to join Mark on the Pain Pod,
- 40:11Speaker 1: send us an email to publish your at pharmacypodcast dot com,
- 40:16Speaker 1: and make sure to share the show and subscribe on
- 40:18Speaker 1: your favorite podcast directory.
- 40:21Speaker 2: Thanks for listening.